Human Adipose-Derived Stem Cells with Great Therapeutic Potential.
Sheykhhasan M., Wong JKL., Seifalian AM.
Clinical Trial on Chronic Kidney Disease, Immune Modulation, Autoimmune Research, published in Curr Stem Cell Res Ther (2019) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Curr Stem Cell Res Ther (2019)
- Country
- United Arab Emirates
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 30973112
- DOI
- 10.2174/1574888X14666190411121528
- Citations
- 40
Abstract (original English)
The potential use of stem cell-based therapies for the repair and regeneration of various tissues and organs offers a paradigm shift in regenerative medicine. The use of either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC) in clinical situations is limited because of regulations and ethical considerations even though these cells are theoretically highly beneficial. While clinically, adipose-derived stem cells (ADSCs) are one of the most widely used types of stem cells used more than five years in clinically setting. It has many advantages including; yields a high number of ADSCs per volume of tissue, high rate of proliferation, anti-fibrotic, anti-apoptotic, anti-inflammation, immunomodulation, and paracrine mechanisms have been demonstrated in various preclinical studies. It is much easier to harvest compared with bone marrow stem cells. Results of clinical studies have demonstrated the potentials of ADSCs for stem cells therapy for a number of clinical disorders. The aim of this paper was to provide an update on the most recent developments of ADSCs, by highlighting the properties and features of ADSCs, critically discussing its clinical benefit and its clinical trials in treatment and regeneration. This is a multi-billion dollars industry with huge interest to clinician, academia and industries.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations